India’s Device Sector At A Crossroads: Will New Policy Push Growth?
This article was originally published in PharmAsia News
The $4.4 billion medical device sector in India has plenty of reasons to grow, but to do so will require a policy framework conducive to innovative products and contentious issues like pricing will need to be resolved by evidence-based decisions, industry says.
You may also be interested in...
MUMBAI - India's medical device market is set to nearly double to around $5 billion by 2012 from $2.75 billion in 2008, spurred by improving healthcare infrastructure including new hospitals, clinics, and laboratories, along with new approaches to healthcare delivery like telemedicine
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.